Boston Scientific Knew of Pacemaker Battery Problems for Years

Why It Matters

The defect jeopardizes patient safety and could trigger costly litigation, while exposing gaps in FDA monitoring of high‑risk medical devices.

Key Takeaways

• Boston Scientific knew battery issues for years
• Faulty Accolade pacemakers affect ~200,000 units
• FDA found failures in 2019‑2023 test batteries
• Recall issued December 2024, six months after death
• Patient deaths highlight regulatory oversight gaps

Pulse Analysis

Pacemakers are a cornerstone of cardiac care, and manufacturers like Boston Scientific dominate a market valued at tens of billions of dollars. The reliability of the device’s power source is critical; a battery failure can abruptly halt life‑sustaining therapy. Over the past decade, advances in lithium‑ion chemistry have promised longer runtimes, yet internal testing at Boston Scientific flagged unexpected degradation patterns as early as 2018, suggesting a systemic flaw that went unaddressed for years.

The Accolade model’s malfunction came to public attention after the tragic death of Gladys Knepper, whose device’s battery failed despite a recent implant. Subsequent investigations uncovered that the company’s own factory tests had recorded similar failures, and FDA inspectors later identified dozens of defective test batteries manufactured between 2019 and 2023. Boston Scientific’s recall in December 2024 covered about 13 percent of its pacemaker inventory—roughly 200,000 units—yet the broader issue points to a lapse in both corporate risk management and regulatory surveillance.

For the medical‑device industry, the episode underscores the need for more rigorous post‑market surveillance and transparent reporting mechanisms. Stakeholders—from physicians to investors—must demand tighter FDA oversight and real‑time data sharing to prevent repeat incidents. Legal exposure for Boston Scientific could be significant, with potential class‑action lawsuits and heightened scrutiny from health‑care payers. Moving forward, manufacturers are likely to invest in more robust battery validation protocols and adopt predictive analytics to flag early signs of failure, aiming to restore confidence in life‑critical implantable technologies.